- The state of Washington said Friday it has selected AbbVie to provide hepatitis C medication through an unconventional subscription payment program that seeks to expand patient access while containing drug costs.
- The contract is part of the state’s plan to eliminate the common viral infection by 2030. “Last year, I committed Washington to a first-in-the-nation approach to eliminate hepatitis C in our state in the next 10 years,” Gov. Jay Inslee said. “This is a great step in helping us achieve that goal.”
- Washington’s selection of AbbVie mimics a move by Louisiana, which last month chose a Gilead subsidiary to provide hepatitis C drugs through a similar program. In both programs, the state effectively pays for an unlimited license to treat residents with these therapies, which has been dubbed a “Netflix model.”
Read more insights from BioPharmaDive here
Read the press release from the Washington State Health Care Authority here
